At a glance
Summary
Revolution Medicines closed at $207.88 for the week ended 28 August, down 0.8% but still up 10.9% over four weeks and 39.3% over 12 weeks. The Trend Signal remains active with 51 of the past 52 weeks active, while activity pressure is positive and relative strength remains favourable. The caution is valuation and participation: the stock trades 41.5% above its weekly Trend Line and 228.3% above Sharemaestro Fair Value, while volume matched the 13-week average at 11.9 million shares rather than confirming with a heavier print.
- RVMD slipped 0.8% on the week to $207.88, but the broader move remains powerful with a 39.3% 12-week gain and a 447.5% 52-week return.
- The weekly Trend Signal is active, supported by 98.1% trend breadth for the stock, with price 41.5% above the $146.94 Trend Line.
- Participation was adequate rather than emphatic: latest volume of 11.9 million shares was 1.0x the 13-week average and 0.9x the 52-week average.
- Relative strength is still positive at 66.62, but it has cooled 9.5% over four weeks, adding nuance to the otherwise constructive setup.
- The main risk is distance from value and prior advance: RVMD trades 228.3% above Sharemaestro Fair Value and sits only 7.3% below its 52-week high of $224.31.
Company analysis
The move in context
Near-high pricing with a softer weekly finish
Revolution Medicines, a $45.3 billion clinical-stage oncology company focused on RAS-addicted cancers, ended the latest week at $207.88, down 0.8%. That pause does little to erase the larger advance: the stock is up 10.9% over four weeks, 39.3% over 12 weeks and 103.8% over 26 weeks.
The close sits in the top decile of its 52-week range at 91.2%, just 7.3% below the $224.31 high and far above the $37.88 low. That position confirms strong demand, but it also raises the bar for fresh buying interest because the stock is already priced well above both its weekly Trend Line and Sharemaestro Fair Value.
Trend remains active, but the signal is not freshly renewed
Sharemaestro’s Trend backdrop is active and unusually persistent, with 51 active weeks out of the past 52. Price remains 41.5% above the $146.94 Trend Line, keeping the weekly regime constructive despite the latest modest decline.
Market Dynamics are mixed rather than one-sided. Activity pressure is positive at 1.60 and has improved over four weeks, but the signal state shows no fresh buy. Relative strength is also positive at 66.62, although the 9.5% four-week deterioration suggests momentum is still favourable but less forceful than it was earlier in the move.
Healthcare and biotech context supports the setup
RVMD continues to stand out inside Healthcare and Biotechnology. The broader US Healthcare group fell 1.5% for the week, while RVMD’s 0.8% decline ranked 42nd among the 100-stock sector sample. Over 12 weeks, the stock’s 39.3% gain ranks ninth in that Healthcare group, comfortably ahead of the sector average of 17.0%.
Within US Biotechnology, the industry average weekly return was weaker at minus 2.9%, while the group’s 12-week average gain was 31.7%. RVMD’s 12-week return is ahead of that benchmark, with active Trend, positive Market Dynamics and positive Relative Strength readings in an industry where 76% of names have active weekly trends and 66% show positive relative strength.
Volume is the confirmation gap to watch
The latest week traded 11.9 million shares, exactly in line with the 13-week average and below the 52-week average of 13.3 million. That is enough participation to avoid a liquidity warning, but not enough to show strong confirmation behind a stock sitting close to its high after a large multi-month run.
The volume history shows why this matters. April’s 54.1% weekly jump came on 45.3 million shares, a clear participation spike, while the latest 0.8% decline came on normal turnover. The next move will carry more weight if volume expands above recent norms, particularly above the 1.5x participation level flagged in the watch list.
Risk is mostly about distance, not breakdown
The risk profile is still supported by favourable skew: RVMD has logged 34 positive weeks against 18 negative weeks over the 52-week window, with average gains of 7.7% compared with average losses of 3.5%. Recent volatility has also cooled, with 13-week weekly-return volatility at 4.5% versus a 52-week base of 11.1%.
The counterpoint is valuation distance and reversal sensitivity. The stock trades 228.3% above Sharemaestro Fair Value at $63.33, and the data flags 13 recent reversal markers in the smart-money record. For the coming week, the key checks are whether the Trend Line remains comfortably below price, whether activity pressure continues to improve, and whether relative strength stabilises after its recent cooling.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line65.0%
Positive Relative Strength55.0%
US Biotechnology
100 tracked companiesAbove Trend Line76.0%
Positive Relative Strength66.0%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 51-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Next-week expectancy is positive at 55.37% based on similar historical setup states.
What needs caution
- 13 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/rvmd-39-percent-quarter-valuation-risk-near-high/.
Follow new Sharemaestro research through the RSS feed or JSON feed.